ProCE Banner Activity


The Burden of Skin and Soft Tissue Infections: Epidemiology, Clinical Presentation, and Diagnosis


In this case-based discussion, learn about the prevalence and impact of skin and soft tissue infections, differences in clinical presentation and etiology between purulent and nonpurulent infections, and complications that should be ruled out prior to initiating treatment.

Pharmacists: 0.25 contact hour (0.025 CEUs)

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: June 14, 2023

Expiration: June 13, 2024

No longer available for credit.



Martin Krsak

Martin Krsak, MD, MSc, FASAM

Associate Professor
Department of Infectious Diseases
Colorado University School of Medicine
Aurora, Colorado

Provided by

Provided by Clinical Care Options, LLC, in partnership with ProCE, LLC and the Society of Infectious Diseases Pharmacists (SIDP).

ProCE Banner


Supported by an educational grant from Melinta Therapeutics.

Melinta Therapeutics



ProCE Banner

Society of Infectious Diseases Pharmacists (SIDP)

ProCE Banner

Target Audience

This program is intended for physicians, pharmacists, and other healthcare professionals who care for patients with ABSSSIs, including both specialists and generalists.

Program Learning Goal

The goal of this activity is to improve learners’ knowledge and competence in management of ABSSSIs, including appropriate utilization of LALs.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Formulate treatment plans for patients with ABSSSIs, including appropriate integration of LALs into care


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Martin Krsak, MD, MSc, FASAM

Associate Professor
Department of Infectious Diseases
Colorado University School of Medicine
Aurora, Colorado

Martin Krsak, MD, MSc, FASAM: consultant/advisor/speaker: Melinta; researcher: AbbVie.

The planners and content peer reviewers from Clinical Care Options, LLC, ProCE, LLC, and the Society of Infectious Diseases Pharmacists (SIDP) do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 14, 2023, through June 13, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC, ProCE, LLC and the Society of Infectious Diseases Pharmacists (SIDP). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-9999-23-167-H01-P .

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.